• IR
  • IR
  • Career
  • Career Opportunities
  • Student Programs
  • Contact Us
  • Contact Us
  • Products

    Frontier Biotechnologies Inc.(Nanjing)


  • 2018-09-25  14:55:25
  • AB001, a new transdermal topical patch, is a musculoskeletal joint pain treatment, currently under clinical development. Through collaboration with ABsize, AB001's Phase II clinical trial for treating lower back pain has been completed in the United States. The clinical data demonstrates that AB001 provides superior pain relief for patients with chronic lower back pain compared to placebo. AB001 minimizes systemic drug exposure with limited side effects that are common in oral therapies. Frontier Biotech also filed an Investigational New Drug (IND) application for AB001 in China and was granted approval by the National Medical Products Administration (NMPA) in March 2019. Phase I bridging pharmacokinetic study will be carried out soon and followed by the critical Phase III clinical trial in the near future.

    Develop Innovative Therapies to Better Human Lives